ArticleNature communications2023
Monitoring transmission intensity of trachoma with serology.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Seroreversion to Chlamydia trachomatis Pgp3 Antigen Among Children in a Hyperendemic Region of Amhara, Ethiopia.The Journal of infectious diseases · 2024Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Discrepancy Between Active Trachoma and Tests of Chlamydial Infection in Alto Amazonas, Peru.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Observational
- Integrated serosurveillance to assess disease elimination in coastal Ecuador: onchocerciasis, yaws, and trachoma.medRxiv : the preprint server for health sciences · 2026Article
- Hotspot-based integrated serosurveillance of neglected tropical diseases, malaria, and vaccine-preventable diseases in urban Guyana.Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Data Resource Profile: Global Trachoma Serology Data Repository.International journal of epidemiology · 2025Article
- serocalculator, an R package for estimating seroincidence from cross-sectional serological data.medRxiv : the preprint server for health sciences · 2025Article
- Female Sex Workers in the Amazon Region of Brazil Are at High Risk ofMicroorganisms · 2025Article
- Characterizing trachoma elimination using serology.Nature communications · 2025Article
- Cost-effectiveness of adding measurement of Chlamydia trachomatis infection and serology to trachoma prevalence surveys in Tanzania and Mozambique.PLoS neglected tropical diseases · 2025Article
- Trachoma.Lancet (London, England) · 2025Review
- Integrated serological surveillance for neglected tropical diseases, vaccine-preventable diseases, and arboviruses in Samoa, 2018.Scientific reports · 2025Article
- Prevalence of ocular Chlamydia trachomatis infection and antibodies within districts persistently endemic for trachoma, Amhara, Ethiopia.PLoS neglected tropical diseases · 2025Article
- Seroprevalence, incidence estimates, and environmental risk factors for dengue, chikungunya, and Zika infection amongst children living in informal urban settlements in Indonesia and Fiji.BMC infectious diseases · 2025Article
- Seroepidemiology of trachoma in a low prevalence region receiving annual mass azithromycin distribution in Maradi, Niger.PLoS neglected tropical diseases · 2024Article
- Seroprevalence, incidence estimates, and environmental risk factors for dengue, chikungunya, and Zika infection amongst children living in informal urban settlements in Indonesia and Fiji.Research square · 2024Article
- Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.Scientific reports · 2024Article
- Serological Responses to Trachoma Antigens prior to the Start of Mass Drug Administration: Results from Population-Based Baseline Surveys, North Darfur, Sudan.The American journal of tropical medicine and hygiene · 2024Article
- Trachoma: The Last Decade?Ophthalmic epidemiology · 2023Article
Corrections and comments
- Update of
Authors and funding
27 authors at 15 institutions in 6 countries.
Funding
Abstract
Trachoma, caused by ocular Chlamydia trachomatis infection, is targeted for global elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor C. trachomatis transmission, we collated IgG responses to Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1-9 years in 14 populations. We demonstrate that age-seroprevalence curves consistently shift along a gradient of transmission intensity: rising steeply in populations with high levels of infection and active trachoma and becoming flat in populations near elimination. Seroprevalence (range: 0-54%) and seroconversion rates (range: 0-15 per 100 person-years) correlate with PCR prevalence (r: 0.87, 95% CI: 0.57, 0.97). A seroprevalence threshold of 13.5% (seroconversion rate 2.75 per 100 person-years) identifies clusters with any PCR-identified infection at high sensitivity ( >90%) and moderate specificity (69-75%). Antibody responses in young children provide a robust, generalizable approach to monitor population progress toward and beyond trachoma elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.